Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Pre-Tax Margin

Income before tax as a percentage of revenue.

Valneva SENASDAQ: VALN

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -101.1%

Pre-tax margin was -101.1% in Q1 FY2026, down 85.4 pp from a year earlier. On a trailing-twelve-month basis it was -88.0%, down 46.0 pp year over year. Over 3 fiscal years it narrowed by 25.3 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-101.1%+6.0 pp QoQ
Last fiscal yearDec 2025
-65.3%-58.6 pp YoY
LTMMar 2026
-88.0%-46.0 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-85.4 pp——
1 year-58.6 pp——
3 years-25.3 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-65.3%
Year-over-year change
-58.6pp

Pre-Tax Margin vs competitors

How VALN compares with its peers on the latest reported figures

  • VALN's LTM Mar 2026 pre-tax margin of -88.0% is the 2nd highest of the 7 companies compared; the peer median is -390.7%.
  • Its year-over-year change of -46.0 pp is the 3rd highest of 7, against a peer median of -88.1 pp.
  • Over three fiscal years its change of -25.3 pp compares with a peer median of -148.1 pp.
VALN Competitors Peer median
Pre-Tax Margin for VALN and competitors
Company Period LTM level YoY 3-year change
NVAXNovavax, Inc.LTM Mar 2026-14.5% -53.4 pp+80.2 pp
VALNValneva SELTM Mar 2026-88.0% -46.0 pp-25.3 pp
MRNAModerna, Inc.LTM Sep 2026-108.1% +33.9 pp-193.1 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-173.5% -122.7 pp-103.0 pp
IBRXImmunityBio, Inc.LTM Sep 2026-607.9% -185.5 pp+173558.8 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-675.4% +2100.4 pp-685.2 pp
INOInovio Pharmaceuticals, Inc.FY2025-130000.0% -80745.7 pp-127273.3 pp
PCVXVaxcyte, Inc.FY2025— ——
Peer median (excluding VALN) -390.7%-88.1 pp-148.1 pp

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.